Benecchi Christopher 4
4 · Sage Therapeutics, Inc. · Filed Feb 15, 2024
Insider Transaction Report
Form 4
Benecchi Christopher
Chief Operating Officer
Transactions
- Award
Common Stock
2024-02-13+13,500→ 19,430 total - Award
Stock Option (Right to Buy)
2024-02-13+27,000→ 27,000 totalExercise: $23.02Exp: 2034-02-13→ Common Stock (27,000 underlying)
Footnotes (3)
- [F1]Consists of shares of common stock issuable under 13,500 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on February 13, 2025.
- [F2]Reflects beneficial ownership balance which includes 670 shares purchased on June 30, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.
- [F3]The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 6,750 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 20,250 shares vesting in 36 equal monthly installments thereafter.